Telomir Pharmaceuticals, Inc.
corporate_fare Company Profile
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for TELO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for TELO spans 10-Q, S-3, 8-K.
Recent high-impact activity:
- Telomir Q3 Loss Narrows to $0.7M; Cash Runway Extended Into Q4 2027
- Telomir Registers Resale of 5.29M PIPE Shares, Making October Overhang Tradable
- Telomir Raises $5.6M in PIPE at $1.16/Share; DeJoria Adds $1M
- Telomir Raises $5.6M PIPE at $1.16/Share; DeJoria Adds $1M to Fund TNBC Trial
- Telomir Flags Going Concern Doubt, Cash Only Through Q1 2027
Financial Snapshot
Short Interest & Short Volume
11.90 days to coverFINRA reported short interest of 750,539 shares in TELO as of the October 30, 2026 settlement, a 2.5% decrease from the prior period — about 11.9 days to cover at its recent average daily volume. On November 20, 2026, 47.2% of TELO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TELO, detected from its recent SEC filings.
Resale Registration for PIPE Shares · Overhang Is About 7% of Shares
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →